{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer&page=22&q=EGFR", "query": { "q": "EGFR", "condition": "Non-Small Cell Lung Cancer", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 533, "total_pages": 54, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer&page=23&q=EGFR&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer&page=21&q=EGFR&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T13:47:36.125Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03778229", "title": "Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma" ], "interventions": [ { "name": "osimertinib", "type": "DRUG" }, { "name": "savolitinib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 367, "start_date": "2019-01-09", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-15T13:47:36.125Z", "location_count": 11, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03778229" }, { "nct_id": "NCT03318939", "title": "Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC" ], "interventions": [ { "name": "Poziotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 648, "start_date": "2017-10-11", "completion_date": "2023-04-03", "has_results": true, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-15T13:47:36.125Z", "location_count": 43, "location_summary": "Phoenix, Arizona • Arcadia, California • Duarte, California + 37 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03318939" }, { "nct_id": "NCT03392246", "title": "A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Osimertinib", "type": "DRUG" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2018-01-31", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-15T13:47:36.125Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Durham, North Carolina", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03392246" }, { "nct_id": "NCT01221077", "title": "Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "OSI-906", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2011-04-08", "completion_date": "2014-09-01", "has_results": false, "last_update_posted_date": "2025-11-18", "last_synced_at": "2026-10-15T13:47:36.125Z", "location_count": 13, "location_summary": "La Jolla, California • Tampa, Florida • Weston, Florida + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Weston", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01221077" }, { "nct_id": "NCT06750185", "title": "Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BNT317 DL1", "type": "BIOLOGICAL" }, { "name": "BNT317 DL2", "type": "BIOLOGICAL" }, { "name": "BNT317 DL3", "type": "BIOLOGICAL" }, { "name": "BNT317 DL4", "type": "BIOLOGICAL" }, { "name": "BNT317 DL5", "type": "BIOLOGICAL" }, { "name": "BNT317 DL6", "type": "BIOLOGICAL" }, { "name": "BNT317 selected DLA", "type": "BIOLOGICAL" }, { "name": "BNT317 selected DLB", "type": "BIOLOGICAL" }, { "name": "SoC chemotherapy 1", "type": "DRUG" }, { "name": "SoC chemotherapy 2", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 248, "start_date": "2025-01-13", "completion_date": "2031-04", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-15T13:47:36.125Z", "location_count": 7, "location_summary": "Louisville, Kentucky • Grand Rapids, Michigan • Huntersville, North Carolina + 4 more", "locations": [ { "city": "Louisville", "state": "Kentucky" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "East Providence", "state": "Rhode Island" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06750185" }, { "nct_id": "NCT01649284", "title": "Afatinib Expanded Access Program", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "afatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2012-07", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2016-11-30", "last_synced_at": "2026-10-15T13:47:36.125Z", "location_count": 66, "location_summary": "Mobile, Alabama • Goodyear, Arizona • Hot Springs, Arkansas + 59 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01649284" }, { "nct_id": "NCT04695847", "title": "M1231 in Participants With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumors", "Esophageal Cancer", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "M1231", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2021-01-13", "completion_date": "2023-06-23", "has_results": false, "last_update_posted_date": "2023-07-07", "last_synced_at": "2026-10-15T13:47:36.125Z", "location_count": 2, "location_summary": "Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04695847" }, { "nct_id": "NCT00063388", "title": "Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2003-05", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2010-04-12", "last_synced_at": "2026-10-15T13:47:36.125Z", "location_count": 8, "location_summary": "Aventura, Florida • Miami Beach, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Aventura", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "South Bend", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00063388" }, { "nct_id": "NCT04900935", "title": "Patient-centered, Optimal Integration of Survivorship and Palliative Care", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage IV Non-small Cell Lung Cancer", "Targeted Therapy", "Nonsmall Cell Lung Cancer", "Carcinoma, Non-Small-Cell Lung", "ALK-positive Non-small Cell Lung Cancer", "EGFR Positive Non-small Cell Lung Cancer", "Palliative Care", "Survivorship" ], "interventions": [ { "name": "POISE", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2023-09-29", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2025-11-24", "last_synced_at": "2026-10-15T13:47:36.125Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04900935" }, { "nct_id": "NCT02729298", "title": "First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "EGFR Positive Non-small Cell Lung Cancer", "Colorectal Carcinoma", "Recurrent Ovarian Carcinoma", "BRAF-Mutated Melanoma" ], "interventions": [ { "name": "TP-0903", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 177, "start_date": "2016-12-14", "completion_date": "2022-06-29", "has_results": false, "last_update_posted_date": "2023-11-14", "last_synced_at": "2026-10-15T13:47:36.125Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Denver, Colorado + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02729298" } ] }